Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'

J Hepatol. 2001 Jul;35(1):134-46. doi: 10.1016/s0168-8278(01)00092-7.


UDCA exerts its beneficial effect in liver diseases through a diverse, probably, complementary array of mechanisms. The clinical use and efficacy of UDCA in PBC have been evident. UDCA may also have a place in the management of PSC, ICP, cystic fibrosis, PFIC and GVHD involving the liver, although, more studies are needed to further determine its therapeutic potential in these diseases and in other hepatobiliary disorders such as liver allograft rejection, drug and TPN-induced cholestasis, NASH, and alcoholic liver disease.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Bile Duct Diseases / drug therapy*
  • Bile Duct Diseases / physiopathology*
  • Chemical Phenomena
  • Chemistry, Physical
  • Humans
  • Liver Diseases / drug therapy*
  • Liver Diseases / physiopathology*
  • Ursodeoxycholic Acid / chemistry
  • Ursodeoxycholic Acid / pharmacology
  • Ursodeoxycholic Acid / physiology*
  • Ursodeoxycholic Acid / therapeutic use


  • Ursodeoxycholic Acid